Influence of episodes of intermittent viremia ("Blips") on immune responses and viral load rebound in successfully treated HIV-infected patients

AIDS Research and Human Retroviruses

Volumn 29, Issue 1, 2013, Pages 68-76

  Castro, Pedro ^a   Plana, Montserrat ^b   González, Raquel ^c,d   López, Anna ^b   Vilella, Anna ^c,d   Nicolas, Jose M ^a   Gallart, Teresa ^b,c   Pumarola, Tomàs ^c   Bayas, José M ^c   Gatell, José M ^c   García, Felipe ^c  

^a HOSPITAL CLÍNIC   (Spain)

^b INSTITUT D INVESTIGACIONS BIOMÈDIQUES AUGUST PI I SUNYER IDIBAPS   (Spain)

^c UNIVERSITY OF BARCELONA   (Spain)

^d CENTRE FOR RESEARCH IN ENVIRONMENTAL EPIDEMIOLOGY CREAL   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

CD4 ANTIGEN; CD45RA ANTIGEN; CHICKENPOX VACCINE; DIPHTHERIA PERTUSSIS TETANUS VACCINE; DIPHTHERIA TETANUS VACCINE; HEPATITIS A VACCINE; HEPATITIS B VACCINE; HUMAN IMMUNODEFICIENCY VIRUS ANTIGEN; INFLUENZA VACCINE; MEASLES MUMPS RUBELLA VACCINE; PLACEBO; PNEUMOCOCCUS VACCINE; VARICELLA ZOSTER VACCINE; VIRUS RNA; VIRUS VACCINE;

ADULT; ARTICLE; CD4 LYMPHOCYTE COUNT; CD4+ T LYMPHOCYTE; CELLULAR IMMUNITY; CLINICAL ARTICLE; EPISODES OF INTERMITTENT VIREMIA; FEMALE; GENOTYPE; HEPATITIS C VIRUS; HETEROSEXUALITY; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HOMOSEXUALITY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNE RESPONSE; IMMUNOLOGICAL PARAMETERS; INFECTION RISK; INTRAVENOUS DRUG ABUSE; LIMIT OF DETECTION; LIMIT OF QUANTITATION; LYMPHOCYTE PROLIFERATION; MALE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); REBOUND; RETROSPECTIVE STUDY; T LYMPHOCYTE ACTIVATION; T LYMPHOCYTE SUBPOPULATION; TREATMENT DURATION; VIREMIA; VIRUS LOAD; VIRUS MUTATION; VIRUS REPLICATION;

ADULT; ANTI-HIV AGENTS; DOUBLE-BLIND METHOD; FEMALE; HIV INFECTIONS; HUMANS; IMMUNITY, CELLULAR; MALE; MIDDLE AGED; RETROSPECTIVE STUDIES; T-LYMPHOCYTE SUBSETS; VIRAL LOAD; VIRAL VACCINES; VIREMIA;

EID: 84871905533     PISSN: 08892229     EISSN: 19318405     Source Type: Journal    
DOI: 10.1089/aid.2012.0145     Document Type: Article

References (46)

1. Havlir DV, Bassett R, Levitan D, et al.: Prevalence and predictive value of intermittent viremia with combination HIV therapy. JAMA 2001;286:171-179.
2. Raboud JM, Rae S, Woods R, Harris M, and Montaner JS: Consecutive rebounds in plasma viral load are associated with virological failure at 52 weeks among HIV-infected patients. AIDS 2002;16:1627-1632.
3. Mira JA, Macias J, Nogales C, et al.: Transient rebounds of low-level viraemia among HIV-infected patients under HAART are not associated with virological or immunological failure. Antivir Ther 2002;7:251-256.
4. Sklar PA, Ward DJ, Baker RK, et al.: Prevalence and clinical correlates of HIV viremia ('blips') in patients with previous suppression below the limits of quantification. AIDS 2002; 16:2035-2041.
5. Greub G, Cozzi-Lepri A, Ledergerber B, et al.: Intermittent and sustained low-level HIV viral rebound in patients receiving potent antiretroviral therapy. AIDS 2002;16:1967- 1969.
6. Karlsson AC, Younger SR, Martin JN, et al.: Immunologic and virologic evolution during periods of intermittent and persistent low-level viremia. AIDS 2004;18:981-989.
7. Papasavvas E, Kostman JR, Thiel B, et al.: HIV-1-specific CD4 + T cell responses in chronically HIV-1 infected blippers on antiretroviral therapy in relation to viral replication following treatment interruption. J Clin Immunol 2006;26: 40-54.
8. Ortiz GM, Hu J, Goldwitz JA, et al.: Residual viral replication during antiretroviral therapy boosts human immunodeficiency virus type 1-specific CD8+ T-cell responses in subjects treated early after infection. J Virol 2002;76:411-415.
9. Alatrakchi N, Duvivier C, Costagliola D, et al.: Persistent low viral load on antiretroviral therapy is associated with T cellmediated control of HIV replication. AIDS 2005;19:25-33.
10. Cohen Stuart JW, Wensing AM, Kovacs C, et al.: Transient relapses (''blips'') of plasma HIV RNA levels during HAART are associated with drug resistance. J Acquir Immune Defic Syndr 2001;28:105-113.
11. Miller LG, Golin CE, Liu H, et al.: No evidence of an association between transient HIV viremia (''blips'') and lower adherence to the antiretroviral medication regimen. J Infect Dis 2004;189:1487-1496.
12. Sungkanuparph S, Overton ET, Seyfried W, et al.: Intermittent episodes of detectable HIV viremia in patients receiving nonnucleoside reverse- transcriptase inhibitor-based or protease inhibitor-based highly active antiretroviral therapy regimens are equivalent in incidence and prognosis. Clin Infect Dis 2005;41:1326-1332.
13. Martinez V, Marcelin AG, Morini JP, et al.: HIV-1 intermittent viraemia in patients treated by non-nucleoside reverse transcriptase inhibitor-based regimen. AIDS 2005;19:1065-1069.
14. Macias J, Palomares JC, Mira JA, et al.: Transient rebounds of HIV plasma viremia are associated with the emergence of drug resistance mutations in patients on highly active antiretroviral therapy. J Infect 2005;51:195-200.
15. Easterbrook PJ, Ives N, Waters A, et al.: The natural history and clinical significance of intermittent viraemia in patients with initial viral suppression to < 400 copies/ml. AIDS 2002;16:1521-1527.
16. Ostrowski SR, Katzenstein TL, Thim PT, et al.: Low-level viremia and proviral DNA impede immune reconstitution in HIV-1-infected patients receiving highly active antiretroviral therapy. J Infect Dis 2005;191:348-357.
17. Castro P, Plana M, Gonzalez R, et al.: Influence of a vaccination schedule on viral load rebound and immune responses in successfully treated HIV-infected patients. AIDS Res Hum Retroviruses 2009;25(12):1249-1259.
18. Libois A, Lopez A, Garcia F, et al.: Dynamics of T cells subsets and lymphoproliferative responses during structured treatment interruption cycles and after definitive interruption of HAART in early chronic HIV Type-1-infected patients. AIDS Res Hum Retroviruses 2006;22:657-666.
19. Garcia F, Plana M, Ortiz GM, et al.: The virological and immunological consequences of structured treatment interruptions in chronic HIV-1 infection. AIDS 2001;15:F29-F40.
20. Plana M, Garcia F, Gallart T, et al.: Lack of T-cell proliferative response to HIV-1 antigens after 1 year of highly active antiretroviral treatment in early HIV-1 disease. Immunology Study Group of Spanish EARTH-1 Study. Lancet 1998;352: 1194-1195.
21. Oxenius A, Price DA, Easterbrook PJ, et al.: Early highly active antiretroviral therapy for acute HIV-1 infection preserves immune function of CD8+ and CD4 + T lymphocytes. Proc Natl Acad Sci USA 2000;97:3382-3387.
22. Plana M, Garcia F, Oxenius A, et al.: Relevance of HIV-1- specific CD4 + helper T-cell responses during structured treatment interruptions in patients with CD4+ T-cell nadir above 400/mm3. J Acquir Immune Defic Syndr 2004;36:791- 799.
23. Garcia F, Lejeune M, Climent N, et al.: Therapeutic immunization with dendritic cells loaded with heat-inactivated autologous HIV-1 in patients with chronic HIV-1 infection. J Infect Dis 2005;191:1680-1685.
24. Nettles RE, Kieffer TL, Kwon P, et al.: Intermittent HIV-1 viremia (blips) and drug resistance in patients receiving HAART. JAMA 2005;293:817-829.
25. Moore AL, Youle M, Lipman M, et al.: Raised viral load in patients with viral suppression on highly active antiretroviral therapy: Transient increase or treatment failure? AIDS 2002;16:615-618.
26. Di Mascio M, Markowitz M, Louie M, et al.: Viral blip dynamics during highly active antiretroviral therapy. J Virol 2003;77:12165-12172.
27. Ramratnam B, Ribeiro R, He T, et al.: Intensification of antiretroviral therapy accelerates the decay of the HIV-1 latent reservoir and decreases, but does not eliminate, ongoing virus replication. J Acquir Immune Defic Syndr 2004;35: 33-37.
28. De Rosa SC, Lu FX, Yu J, et al.: Vaccination in humans generates broad T cell cytokine responses. J Immunol 2004; 173:5372-5380.
29. Schmitz JE, Kuroda MJ, Santra S, et al.: Control of viremia in simian immunodeficiency virus infection by CD8+ lymphocytes. Science 1999;283:857-860.
30. Pontesilli O, Kerkhof-Garde S, Notermans DW, et al.: Functional T cell reconstitution and human immunodeficiency virus-1-specific cell-mediated immunity during highly active antiretroviral therapy. J Infect Dis 1999;180:76-86.
31. Papasavvas E, Grant RM, Sun J, et al.: Lack of persistent drug-resistant mutations evaluated within and between treatment interruptions in chronically HIV-1-infected patients. AIDS 2003;17:2337-2343.
32. Chehimi J, Campbell DE, Azzoni L, et al.: Persistent decreases in blood plasmacytoid dendritic cell number and function despite effective highly active antiretroviral therapy and increased blood myeloid dendritic cells in HIV-infected individuals. J Immunol 2002;168:4796-4801.
33. Azzoni L, Papasavvas E, Chehimi J, et al.: Sustained impairment of IFN-gamma secretion in suppressed HIV-infected patients despite mature NK cell recovery: Evidence for a defective reconstitution of innate immunity. J Immunol 2002; 168:5764-5770.
34. Pantaleo G, Soudeyns H, Demarest JF, et al.: Evidence for rapid disappearance of initially expanded HIV-specific CD8 + T cell clones during primary HIV infection. Proc Natl Acad Sci USA 1997;94:9848-9853.
35. Appay V, Nixon DF, Donahoe SM, et al.: HIV-specific CD8 (+) T cells produce antiviral cytokines but are impaired in cytolytic function. J Exp Med 2000;192:63-75.
36. Napravnik S, Edwards D, Stewart P, et al.: HIV-1 drug resistance evolution among patients on potent combination antiretroviral therapy with detectable viremia. J Acquir Immune Defic Syndr 2005;40(1):34-40.
37. Garcia-Gasco P, Maida I, Blanco F, et al.: Episodes of lowlevel viral rebound in HIV-infected patients on antiretroviral therapy: Frequency, predictors and outcome. J Antimicrob Chemother 2008;61(3):699-704
38. Buzon MJ, Massanella M, Llibre JM, et al.: HIV-1 replication and immune dynamics are affected by raltegravir intensification of HAART-suppressed subjects. Nat Med 2010;16(4): 460-465.
39. Jackson JB, Piwowar-Manning E, Johnson-Lewis L, et al.: Comparison of versions 1.0 and 1.5 of the UltraSensitive AMPLICOR HIV-1 MONITOR test for subjects with low viral load. J Clin Microbiol 2004;42:2774-2776.
40. Brambilla D, Reichelderfer PS, Bremer JW, et al.: The contribution of assay variation and biological variation to the total variability of plasma HIV-1 RNA measurements. The Women Infant Transmission Study Clinics. Virology Quality Assurance Program. AIDS 1999;13:2269-2279.
41. Schockmel GA, Yerly S, and Perrin L: Detection of low HIV- 1 RNA levels in plasma. J Acquir Immune Defic Syndr Hum Retrovirol 1997;14:179-183.
42. Smit E, Bhattacharya S, Osman H, and Taylor S: Increased frequency of HIV-1 viral load blip rate observed after switching from Roche Cobas Amplicor to Cobas Taqman assay. J Acquir Immune Defic Syndr 2009;51(3):364-365.
43. Verhofstede C, Van WF, Reynaerts J, et al.: Viral load assay sensitivity and low level viremia in HAART treated HIV patients. J Clin Virol 2010;47(4):335-339.
44. Percus JK, Percus OE, Markowitz M, et al.: The distribution of viral blips observed in HIV-1 infected patients treated with combination antiretroviral therapy. Bull Math Biol 2003;65:263-277.
45. Aldous JL and Haubrich RH: Defining treatment failure in resource- rich settings. Curr Opin HIV AIDS 2009;4(6):459-466.
46. Thompson MA, Aberg JA, Cahn P, et al.: Antiretroviral treatment of adult HIV infection: 2010 recommendations of the International AIDS Society-USA panel. JAMA 2010; 304(3):321-333.